Other languages Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Delayed Hong Kong S.E. Other stock markets 03:00:03 2024-05-13 am EDT			5-day change	1st Jan Change
1.44 ^HKD	+1.41%		+1.41%	-1.37%

Apr. 03	Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	MT
Apr. 03	Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	Apr. 03
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	Apr. 03
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting	Mar. 10
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug	Jan. 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne	Jan. 24
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis	Jan. 02
Ascletis Pharma Gets Nod to Trial Acne Drug	Dec. 05
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	Dec. 05
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet	Nov. 13
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication	Nov. 06
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug	23-10-10
Ascletis Pharma Finds Envafolimab Safe to Use in Study	23-09-29
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure	23-09-28
Ascletis Enrolls 120 Patients in Phase 3 Clinical Trial for Combination Treatment for Glioblastoma; Shares Fall 6%	23-09-26
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma	23-09-25
Ascletis' H1 Attributable Loss Narrows as Revenue Jumps	23-08-21
Ascletis Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21
Ascletis Pharma's HIV Drug Clinical Data Presented at Australia Medical Conference	23-07-25
Ascletis Unit Completes Patient Enrollment for Phase 2 Trial for Biliary Cholangitis Drug; Shares Rise 8%	23-07-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Other languages

Filters